Welcome to our dedicated page for Parkervision SEC filings (Ticker: PRKR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for ParkerVision, Inc. (PRKR), a Florida corporation focused on radio-frequency (RF) technologies for advanced wireless communication systems. Through its periodic and current reports, ParkerVision provides detailed information on its operations, financial condition, litigation posture, and capital-raising activities.
Investors can use ParkerVision’s annual reports on Form 10-K and quarterly reports on Form 10-Q to review its RF technology and licensing focus, operating expenses, net losses, contingent payment obligations, and cash flows. These filings also include risk factor discussions that the company references in its press releases, covering topics such as outcomes of patent litigation, interpretations of patent law and claim scope, decisions by the Patent Trial and Appeal Board (PTAB), and market conditions affecting financing.
Current reports on Form 8-K are particularly important for tracking material events. Recent 8-K filings describe registered direct offerings of common stock under ParkerVision’s effective shelf registration statement on Form S-3, including sales to accredited investors and to a director. These filings outline subscription agreements, offering prices, aggregate purchase amounts, and legal opinions regarding the issuance of securities. Other 8-Ks furnish earnings press releases that summarize quarterly and year-to-date financial results and provide context for changes in operating expenses and contingent payment obligations.
Through this filings page, users can access ParkerVision’s real-time updates as they are filed with EDGAR, including 10-K, 10-Q, and 8-K reports, as well as registration statements and prospectus supplements related to its shelf registration. AI-powered tools on the platform can help summarize lengthy filings, highlight key sections such as litigation disclosures, capital structure changes, and risk factors, and make it easier to interpret complex legal and financial language without replacing the full primary documents.
ParkerVision, Inc. is registering for resale 9,387,500 shares of Common Stock under a prospectus supplement dated March 23, 2026, consisting of shares issued, shares issuable upon conversion of convertible notes, and shares issuable upon exercise of options.
The supplement states the company will not receive proceeds from selling shareholders; if the 200,000 Options are exercised for cash, the company would receive up to $42,620. The supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025.
As context, shares outstanding were 147,535,024 as of March 19, 2026. The filing is a resale registration by selling holders under the existing Prospectus (Prospectus dated May 11, 2023).
ParkerVision, Inc. registers 16,638,353 shares of common stock for resale pursuant to a Prospectus Supplement dated March 23, 2026.
The shares are issuable upon conversion of convertible promissory notes dated between May 10, 2022 and August 3, 2022 at a fixed conversion price of $0.13 per share and are being resold by selling shareholders (resale offering). The Prospectus Supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates disclosures.
Context: the company reported 147,535,024 shares outstanding as of March 19, 2026, cash and cash equivalents of $4.4M as of December 31, 2025, and convertible notes principal of $3.1M as of that date.
ParkerVision, Inc. registers 1,578,946 shares of Common Stock for resale under a prospectus supplement dated March 23, 2026. The registration consists of 1,052,631 shares of Common Stock and 526,315 shares issuable upon exercise of outstanding warrants. The company will not receive proceeds from resales by the selling stockholder; if the warrants are exercised for cash, ParkerVision would receive up to $526,315, which it expects to use for general working capital, including payment of litigation expenses.
The supplement incorporates ParkerVision’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and updates the prospectus’ disclosures regarding the company’s patent enforcement-focused business, contingent funding arrangements, convertible debt, and substantial doubt about its ability to continue as a going concern.
ParkerVision, Inc. is registering 13,342,953 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated March 23, 2026.
The registered shares consist of 7,962,722 shares issued under earlier purchase agreements, 3,230,942 shares and 1,619,289 shares underlying warrants issued in March 2021, and 530,000 shares issued for services. The company will not receive proceeds from resale by the selling stockholders, but could receive up to $2,833,756 if the Warrants are exercised for cash; any such proceeds are expected to be used for general working capital, including payment of litigation expenses.
This prospectus supplement updates the Prospectus (dated April 26, 2021) with information from the Company’s Annual Report on Form 10-K filed March 23, 2026. Shares outstanding were 147,535,024 as of March 19, 2026.
ParkerVision, Inc. files a prospectus supplement to register the resale of 5,871,584 shares of Common Stock. The resale consists of shares issued under securities purchase agreements dated April 29, 2020 through August 19, 2020, and the company will receive no proceeds from sales by the selling stockholders.
The supplement attaches the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and updates the base prospectus; it references patent-enforcement-driven licensing efforts, contingent funding arrangements, and going-concern disclosures in the attached Form 10-K.
ParkerVision, Inc. is registering 16,809,295 shares of its common stock for resale by the selling stockholders under a Prospectus Supplement dated March 23, 2026. The resale pool includes shares issuable on conversion of notes, shares issued under purchase agreements and as consideration, and shares issuable upon exercise of warrants.
The company states it will not receive proceeds from sales by the selling stockholders; however, if the Aspire and Tailwinds warrants are exercised for cash, the company would receive up to $3,900,000. Shares outstanding were 147,535,024 as of March 19, 2026.
ParkerVision, Inc. registers 18,014,164 shares of Common Stock for resale by selling stockholders under a prospectus supplement dated March 23, 2026. The registered shares consist of conversions of convertible notes, shares issued for services, and a warrant exercisable into up to 1,800,000 shares.
The company states it will not receive proceeds from sales by the selling stockholders; however, if the Park Consulting Warrant is exercised for cash the company would receive up to $180,000 in gross proceeds. This supplement attaches the company’s Form 10-K for the fiscal year ended December 31, 2025 and updates the prospectus with those disclosures.
ParkerVision, Inc. registered 17,189,660 shares of common stock for resale under a prospectus supplement dated March 23, 2026. The registration aggregates three groups: (i) 1,273,540 shares tied to a 2016 private placement and warrant, (ii) up to 10,000,000 shares issued/issuable under a July 26, 2018 PIPE agreement with Aspire Capital, and (iii) 5,916,120 shares issuable upon conversion of 2018 convertible notes at fixed conversion prices.
The supplement states the company will not receive proceeds from resales by selling stockholders; however, it may receive proceeds if the 2016 warrant or Aspire-issued warrants are exercised. The prospectus supplement incorporates the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and attaches that 10-K as an update.
ParkerVision, Inc. files a Prospectus Supplement registering 12,800,000 shares of Common Stock for resale by selling stockholders under its April 19, 2019 prospectus. The registration covers up to 7,800,000 shares issuable on conversion of certain convertible promissory notes and 5,000,000 shares issuable upon exercise of a five-year warrant.
The company states it will not receive proceeds from resales by selling stockholders; if the warrant is exercised for cash, the company would receive up to $800,000 in gross proceeds, which it expects to use for patent enforcement and working capital. This supplement incorporates the Form 10-K filed March 23, 2026 and updates the Prospectus.
ParkerVision, Inc. reports another year of operating losses with a heavy reliance on patent litigation and licensing as its sole business. The company generated no licensing revenue in 2025 or 2024 and recorded a 2025 net loss of approximately $7.4 million, narrowing from $14.5 million in 2024.
At December 31 2025, ParkerVision held cash and cash equivalents of about $4.4 million, working capital of $2.3 million, and an accumulated deficit near $455.6 million. The auditor cited substantial doubt about its ability to continue as a going concern, reflecting recurring losses and negative operating cash flow.
The balance sheet is highly leveraged by litigation-related financing, including secured and unsecured contingent payment obligations with an estimated fair value of roughly $46.1 million and convertible notes of $3.1 million. To fund operations, the company continues to issue equity and depend on contingent litigation funding, which has led to significant dilution of shareholders.